Discovery of N,4-Di(1H-pyrazol-4-yl)pyrimidin-2-amine-Derived CDK2 Inhibitors as Potential Anticancer Agents: Design, Synthesis, and Evaluation
Biruk Sintayehu Fanta(University of South Australia), Shudong Wang(The University of Adelaide)
Cited by 8
Related Papers
Targeting Mnks for Cancer Therapy
|Oncotarget|2012|138
Targeting CDK9 for treatment of colorectal cancer
|Molecular Oncology|2019|57